News

Methotrexate assay useful in severe pediatric dermatitis, psoriasis


 

AT THE ANNUAL MEETING OF THE SOCIETY FOR PEDIATRIC DERMATOLOGY

"A MTX PG3 less than 30 nmol/L in a child who has failed to respond within 12 weeks suggests that an increase in oral dose, or even a change to subcutaneous [administration], will boost efficacy," she commented.

Mr. Rahman, Dr. Siegfried, and Dr. Paller reported having no relevant financial disclosures.

pwendling@frontlinemedcom.com

Pages

Recommended Reading

Subcutaneous Nodules Linked to Cardiovascular Disease Risk in RA
MDedge Rheumatology
Stroke caution on thalidomide for cutaneous LE
MDedge Rheumatology
Combo may be best rescue therapy for resistant Kawasaki disease
MDedge Rheumatology
Screen all psoriasis patients for hepatitis before immunosuppressive therapy
MDedge Rheumatology
Preimmunosuppresive hepatitis B screening often goes by the wayside
MDedge Rheumatology
Sjögren's syndrome has high long-term complication rate
MDedge Rheumatology
Strategy outlined for treating severe refractory cutaneous lupus
MDedge Rheumatology
Algorithm helps to DETECT pulmonary hypertension in systemic sclerosis
MDedge Rheumatology
Apremilast effects sustained at 1 year in psoriatic arthritis
MDedge Rheumatology
Scleroderma patients suffer from small bowel bacterial overgrowth
MDedge Rheumatology